A randomized, open-label phase 2 study of 2 regimens, gemcitabine plus enzastaurin and single-agent gemcitabine, in patients with locally advanced or metastatic pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2009
At a glance
- Drugs Enzastaurin; Gemcitabine
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Eli Lilly
- 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2007 Status changed from recruiting to in progress.
- 31 Mar 2006 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History